Dopamine Agonist Increases Risk Taking but Blunts Reward-Related Brain Activity
Open Access
- 25 June 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (6) , e2479
- https://doi.org/10.1371/journal.pone.0002479
Abstract
The use of D2/D3 dopaminergic agonists in Parkinson's disease (PD) may lead to pathological gambling. In a placebo-controlled double-blind study in healthy volunteers, we observed riskier choices in a lottery task after administration of the D3 receptor-preferring agonist pramipexole thus mimicking risk-taking behavior in PD. Moreover, we demonstrate decreased activation in the rostral basal ganglia and midbrain, key structures of the reward system, following unexpected high gains and therefore propose that pathological gambling in PD results from the need to seek higher rewards to overcome the blunted response in this system.Keywords
This publication has 18 references indexed in Scilit:
- Reward‐Related Responses in the Human StriatumAnnals of the New York Academy of Sciences, 2007
- Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson DiseaseArchives of Neurology, 2006
- Plasticity of reward neurocircuitry and the 'dark side' of drug addictionNature Neuroscience, 2005
- Knowing good from bad: differential activation of human cortical areas by positive and negative outcomesEuropean Journal of Neuroscience, 2005
- The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) ratsPharmacology Biochemistry and Behavior, 2005
- Pathological gambling is linked to reduced activation of the mesolimbic reward systemNature Neuroscience, 2005
- Amphetamine Modulates Human Incentive ProcessingNeuron, 2004
- Acute administration of the selective D3 receptor antagonist SB‐277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male ratsSynapse, 2003
- Attenuation of Cue-Controlled Cocaine-Seeking by a Selective D3 Dopamine Receptor Antagonist SB-277011-ANeuropsychopharmacology, 2002
- Neurobiological evidence for hedonic allostasis associated with escalating cocaine useNature Neuroscience, 2002